Abstract:Actinobacteria refers to a group of Gram-positive bacteria with higher G + C DNA base content than other groups of bacteria. They belong to one of the largest bacterial genera called Actinomycetes and are known for their enormous ability to adapt to any environment (including the less explored biota such as deep sea or oceans, hydrothermal vents, etc.). It is a well-established fact that the group actinobacteria is pharmacologically very important and is highly efficient in producing secondary metabolites (such as pigments, antibiotics, toxins, alkaloids, etc.). These species have been further screened for many important and novel secondary metabolites that show a range of biological activities including anti-angiogenesis, antibacterial, anticancer, antifungal, anti-inflammatory, antimalaria, anti-parasitic, antioxidant, antitumour, antiviral, etc., to name a few. The secondary metabolites extracted from actinobacteria of the marine milieu have received extensive consideration due to their structural diversity and exceptional biological activities. Some of the actinomycetes genera such as Actinomadura, Actinoplanes, Microbispora, Micromonospora, Nocardia, Pseudonocardia and Sinomonas are known as rare species, which needs to be exploited for its applications in the field of pharmaceuticals (drug discovery). In the current chapter, an assessment is being done on the research conducted with the marine actinobacteria and the secondary metabolites produced by them of pharmaceutical importance. These secondary bioactive substances possess discrete chemical assemblies which may help in the catalysis or synthesis of new drugs. It is believed that the actinobacteria can provide promising and favourable productivity of commercially important bioactive compound with therapeutic value.

Harnessing Gram‐negative bacteria for novel anti‐Gram‐negative antibiotics

Natural Products from Bacillus Subtilis with Antimicrobial Properties

Bacterial Natural Product Drug Discovery for New Antibiotics: Strategies for Tackling the Problem of Antibiotic Resistance by Efficient Bioprospecting

New antibiotics from bacterial natural products

Concepts and Methods to Access Novel Antibiotics from Actinomycetes

Sophisticated natural products as antibiotics

Optimization Of Globomycin Analogs As Novel Gram-Negative Antibiotics

Genome mining and prospects for antibiotic discovery

Alternative natural sources for a new generation of antibacterial agents

The re-emerging role of microbial natural products in antibiotic discovery

Bacterial pathogens: threat or treat (a review on bioactive natural products from bacterial pathogens)

Returning to Nature for the Next Generation of Antimicrobial Therapeutics

Targeting Bacterial Genomes for Natural Product Discovery

Strategies to access biosynthetic novelty in bacterial genomes for drug discovery

The “Three Cs” of Novel Antibiotic Discovery and Production through Synthetic Biology: Biosynthetic Gene Clusters, Heterologous Chassis, and Synthetic Microbial Consortia

Recent Advances in Synthetic Biology Approaches to Optimize Production of Bioactive Natural Products in Actinobacteria

Actinobacteria and Myxobacteria-Two of the Most Important Bacterial Resources for Novel Antibiotics

Recent progress of antibacterial natural products: Future antibiotics candidates

Natural Products from Actinobacteria for Drug Discovery

Harnessing synthetic biology-based strategies for engineered biosynthesis of nucleoside natural products in actinobacteria